ReviewAntibiotics (Basel, Switzerland)2022
Current Positioning against Severe Infections Due to
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Short-Term Within-Host Genomic Diversity and Clone Turnover of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Bloodstream Infections Due to Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial Resistance Patterns and Cumulative Antibiogram of Clinically Significant Bacteria From a Tertiary Hospital in Indonesia.International journal of microbiology · 2026Article
- Parallel single-cell host immune profiling and pathogen genomic characterization inFrontiers in cellular and infection microbiology · 2026Observational
- Molecular epidemiology of extended-spectrum beta-lactamase-producingMicrobial genomics · 2025Article
- Antibiotic Resistance Trends in Carbapenem-Resistant Gram-Negative Pathogens and Eight-Year Surveillance of XDR Bloodstream Infections in a Western Greece Tertiary Hospital.Pathogens (Basel, Switzerland) · 2024Article
- Phage-induced efflux down-regulation boosts antibiotic efficacy.PLoS pathogens · 2024Article
- Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens.Pathogens (Basel, Switzerland) · 2024Review
- Bacterial Infections in Intensive Care Units: Epidemiological and Microbiological Aspects.Antibiotics (Basel, Switzerland) · 2024Review
- Addressing the at-home care needs of patients with multidrug-resistant bacteria: what should we do?European journal of hospital pharmacy : science and practice · 2023Article
- Factors Associated with Extended-Spectrum β-Lactamases and Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review.Journal of clinical medicine · 2023Review
- Machine learning model of imipenem-resistantHealth science reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections due to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.